The authors present a clinical case of a female patient with depression who developed lichen planus during the COVID-19 pandemic and describe the anamnesis, skin and mental status of the patient. The phenomenon of amplified itching in the clinical picture in the post-covid period in the framework of depressive cataesthetic hyperesthesia is considered. A comprehensive psychosomatic assessment of the condition and the inclusion of approaches of psychocorrection in basic dermatotropic therapy contributed to the normalization of mood, rapid and complete reduction of itching, improvement of the skin status and patient's quality of life.

Download full-text PDF

Source
http://dx.doi.org/10.17116/jnevro2022122011122DOI Listing

Publication Analysis

Top Keywords

planus covid-19
8
[lichen planus
4
covid-19 depression
4
depression psychosomatic
4
psychosomatic correlations]
4
correlations] authors
4
authors clinical
4
clinical case
4
case female
4
female patient
4

Similar Publications

New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination.

SAGE Open Med Case Rep

December 2024

Department of Dermatology, College of Medicine, University of Saskatchewan, Regina, SK, Canada.

We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This report adds to the growing evidence of new-onset LP following COVID-19 vaccination and underscores the need for careful reporting, monitoring, and management of vaccine-related adverse effects.

View Article and Find Full Text PDF

Amidst worldwide reports of adverse oral lesions subsequent to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, the current systematic review planned to determine the prevalence of adverse oral events in adult individuals (≥18 years) after SARS-CoV-2 vaccination, emphasizing upon the type and dose of vaccine, time of onset, and underlying pathophysiology. The registered protocol (PROSPERO CRD42023421307), conforming with PRISMA guidelines, included an all-inclusive literature search through online databases, consisting of Scopus, PubMed/MEDLINE, Web of Science, Lilacs, Livivo, and PROSPERO, completed on 2 May 2023, followed by assessment of risk of bias by Joana Briggs Institute Evaluation Checklist. Due to the paucity of literature, case reports and case series were included.

View Article and Find Full Text PDF

Lichen planus (LP) is an inflammatory autoimmune mucocutaneous disease with different forms and presentations. It mainly affects the skin and oral mucosa but could also affect genital mucosa, nails, hair, and, rarely, the larynx and esophagus. Since the start of the COVID-19 era, multiple cutaneous manifestations related to SARS-CoV-2 infection or vaccination have been reported.

View Article and Find Full Text PDF

Lichen planus triggered by COVID-19 vaccination: Comment.

J Family Med Prim Care

August 2024

University Centre for Research and Development Department of Pharmaceutical Sciences, Chandigarh University, Mohali, Punjab, India.

View Article and Find Full Text PDF
Article Synopsis
  • COVID-19 vaccinations, particularly mRNA vaccines, have been linked to exacerbations of immune-mediated inflammatory diseases like psoriasis and hidradenitis suppurativa.
  • Patients with hidradenitis suppurativa who received mRNA vaccines are 3.5 times more likely to experience disease flares compared to those who received non-mRNA vaccines.
  • Additional studies are needed to confirm these findings across larger populations and to better understand the relationship between COVID-19 vaccines and other inflammatory conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!